Zydus Cadila has launched Phase II clinical trials of its Covid-19 vaccine candidate, ZyCoV-D, which showed promise in a Phase I study.
175 volunteers from Belagavi have participated in the phase 2 of the study.
The company completed dosing in the Phase I trial, where the vaccine was found to be safe and well tolerated in healthy participants.
Covaxin developed by Bharat Biotech, Hyderabad has commended its Human clinical trials phase 1 were done on 4 volunteers.
Both the trials are been undergoing in association with Indian Council of Medical Research (ICMR) at Jeevan Rekha Hospital in Belagavi.
Phase 2 of Covaxin has also commenced now.
Phase II clinical trials of ZyCoV-D is for evaluating the safety and immunogenicity of the vaccine in a larger population.
ZyCoV-D is a plasmid DNA vaccine candidate. When delivered into the host cells, the plasmid DNA is known to translate into the viral protein and trigger a strong cellular and humoral immune response.
